Rankings
▼
Calendar
AXSM
Axsome Therapeutics, Inc.
$9B
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$638M
+65.5% YoY
Gross Profit
$591M
92.6% margin
Operating Income
-$169M
-26.5% margin
Net Income
-$183M
-28.7% margin
EPS (Diluted)
$-3.68
Cash Flow
Operating Cash Flow
-$93M
Free Cash Flow
-$93M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$690M
Total Liabilities
$602M
Stockholders' Equity
$88M
Cash & Equivalents
$323M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$638M
$386M
+65.5%
Gross Profit
$591M
$352M
+67.7%
Operating Income
-$169M
-$281M
+39.7%
Net Income
-$183M
-$287M
+36.2%
← Q4 2024
All Quarters
Q1 2025 →
AXSM FY 2025 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena